"The voice for cancer physicians and their patients in Massachusetts."

  • 29 Jun 2018 9:30 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis), a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Read full press release. 

  • 29 Jun 2018 8:48 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved rucaparib (Rubraca; Clovis Oncology), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Read full press release.

  • 29 Jun 2018 8:30 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration osimertinib (Tagrisso; AstraZeneca) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Read full press release.

  • 29 Jun 2018 8:23 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to dabrafenib (Tafinlar; Novartis) and trametinib (Mekinist; Novartis) in combination for the adjuvant treatment of patients with melanoma with BRAF 600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. Read full press release. 

  • 29 Jun 2018 8:16 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved nivolumab and ipilimumab (Opdivo and Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

  • 29 Jun 2018 8:01 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz; Novartis) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC. TSC associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma. Read full press release.

  • 29 Jun 2018 7:48 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved brentuximab vedotin (Adcentris; Seattle Genomics) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Read full press release. 

  • 17 Apr 2018 2:00 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administrator approved everoliums tablets for oral suspension (Afinitor Disperz; Novartis Pharmaceuticals) for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma. Read full press release.

  • 17 Apr 2018 1:52 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted approvals to nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

  • 27 Feb 2018 1:44 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved durvalumab (Infinzi; AstraZeneca) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Read full press release

Upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software